Blog Topic
Policy & Access
The regulatory and access context around GLP-1 and GLP-3 therapies — FDA status, shortage and compounding policy, and how supply changes affect availability. Informational coverage, not legal or medical guidance.
Policy & Access
The Shortage Is Over — But the Access Problem Isn't In February 2025, the FDA officially removed semaglutide from its drug shortage database. On paper, that sounds like a win. In practice…
Stay Informed
Get evidence-based research updates and treatment-landscape guides delivered to your inbox.